Healthcare / BiotechnologyKOSDAQ
$1155.00
-83.00 (-6.70%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-12.4B · quality 52.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
13/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$29.7B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-48.2%
↓Gross Margin
15.3%
↓Debt/Equity
0.46
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-36.1%
FCF CAGR
—
FCF margin
-17.0%
FCF / Net income
0.30x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $28.59B · net income $-16.28B · FCF $-4.86B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $28.59B | $28.59B | $34.47B | $20.70B | $109.79B |
| Net Income | $-16.28B | $-16.28B | $3.09B | $-21.26B | $-435.4M |
| EBITDA | $-9.06B | $-9.06B | $2.10B | $-16.01B | $3.06B |
| EPS | -714.00 | -714.00 | 146.00 | -1336.00 | -28.09 |
| Gross Margin | 15.3% | 15.3% | 29.9% | 24.1% | 12.0% |
| Operating Margin | -35.9% | -35.9% | -15.2% | -23.6% | 2.7% |
| Net Margin | -57.0% | -57.0% | 9.0% | -102.7% | -0.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.46 | 0.46 | 0.28 | 0.28 | 0.09 |
| Current Ratio | 1.14 | 1.14 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-4.86B | $-4.86B | $-14.72B | $-12.40B | $-628010.00 |
| Returns | |||||
| ROE | -48.2% | -48.2% | 7.0% | -56.9% | -0.9% |
| Valuation | |||||
| P/E | — | — | 13.68 | — | — |
| EV/EBITDA | — | — | 20.26 | — | 19.73 |
| P/B | 0.78 | 0.78 | 0.96 | 1.23 | 1.34 |
| Growth & Yield | |||||
| Revenue Growth | -17.1% | -17.1% | 66.6% | -81.2% | — |
| EPS Growth | -589.0% | -589.0% | 110.9% | -4657.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-50.0%
Start / end P/E
n/dx → n/dx
EPS bridge
146.00 → -714.00
Residual
-50.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.